BioLife Solutions, Inc. (NASDAQ:BLFS) Receives $29.00 Average Price Target from Brokerages

Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) have earned an average rating of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $29.00.

Several equities analysts recently commented on the stock. TD Cowen increased their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. HC Wainwright decreased their price target on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Benchmark reissued a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. KeyCorp lifted their price objective on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Finally, Craig Hallum raised their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th.

BioLife Solutions Trading Down 1.6 %

NASDAQ BLFS opened at $26.59 on Tuesday. The stock’s 50-day simple moving average is $25.28 and its two-hundred day simple moving average is $23.91. The company has a market capitalization of $1.23 billion, a price-to-earnings ratio of -25.08 and a beta of 1.91. BioLife Solutions has a twelve month low of $14.50 and a twelve month high of $28.88. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03.

Insider Buying and Selling

In other BioLife Solutions news, EVP Aby J. Mathew sold 10,000 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $23.28, for a total value of $232,800.00. Following the sale, the executive vice president now directly owns 317,716 shares of the company’s stock, valued at approximately $7,396,428.48. The trade was a 3.05 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold a total of 64,259 shares of company stock worth $1,424,708 in the last three months. 2.20% of the stock is owned by corporate insiders.

Institutional Trading of BioLife Solutions

A number of institutional investors and hedge funds have recently bought and sold shares of BLFS. Stifel Financial Corp raised its stake in shares of BioLife Solutions by 5.4% in the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after purchasing an additional 670 shares during the last quarter. Louisiana State Employees Retirement System grew its position in BioLife Solutions by 4.0% during the second quarter. Louisiana State Employees Retirement System now owns 18,300 shares of the medical equipment provider’s stock valued at $392,000 after buying an additional 700 shares during the period. GAMMA Investing LLC increased its holdings in BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 748 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in BioLife Solutions by 5.8% during the second quarter. The Manufacturers Life Insurance Company now owns 13,825 shares of the medical equipment provider’s stock valued at $296,000 after buying an additional 753 shares during the last quarter. Finally, Mark Sheptoff Financial Planning LLC bought a new position in BioLife Solutions in the third quarter worth approximately $28,000. 93.24% of the stock is currently owned by institutional investors.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.